Analyst Reco. Ascendis Pharma A/S

Equities

ASND

US04351P1012

Real-time Estimate Cboe BZX Other stock markets 11:01:38 2023-10-02 am EDT			5-day change	1st Jan Change
92.31 ^USD	-1.43%		-3.41%	-24.47%

Sep. 23	Ascendis Pharma A/S Presents Results from Long-Term enliGHten Trial of TransCon hGH in Pediatric Growth Hormone Deficiency	CI
Sep. 21	Pharma Stocks Lead European Equities Traded in the US as American Depositary Receipts Lower Thursday	MT

Analyst Reco.

Morgan Stanley Adjusts Price Target on Ascendis Pharma to $113 From $109, Maintains Equalweight Rating	Sep. 06	MT
Wedbush Raises Ascendis Pharma's Price Target to $192 From $187 After Model Adjustments, Keeps Outperform Rating	Sep. 06	MT
Wedbush Lifts Ascendis Pharma's Price Target to $187 From $186, Keeps Outperform Rating	Jun. 02	MT
Wedbush Lowers Ascendis Pharma's Price Target to $186 From $195 After Model Adjustments, Keeps Outperform Rating	May. 08	MT
Morgan Stanley Adjusts Ascendis Pharma's Price Target to $109 From $107, Keeps Equalweight Rating	Apr. 28	MT
Credit Suisse Raises Ascendis Pharma's Price Target to $89 From $82 After Q1 Skytrofa Revenue Beat Consensus, Keeps Neutral Rating	Apr. 28	MT
Oppenheimer Downgrades Ascendis Pharma to Perform From Outperform, Removes $148 Price Target	Apr. 05	MT
Citigroup Adjusts Ascendis Pharma Price Target to $146 From $163, Maintains Buy Rating	Apr. 05	MT
Morgan Stanley Downgrades Ascendis Pharma to Equalweight From Overweight, Adjusts Price Target to $108 From $151	Apr. 04	MT
BofA Securities Adjusts Price Target on Ascendis Pharma to $92 From $132, Keeps Buy Rating	Apr. 04	MT
Wells Fargo Cuts Ascendis Pharma's Price Target to $139 From $177, Maintains Overweight Rating	Apr. 03	MT
Evercore ISI Lowers Ascendis Pharma's Price Target to $140 From $160, Maintains Outperform Rating	Apr. 03	MT
Goldman Sachs Lowers Ascendis Pharma's Price Target to $155 From $175, Maintains Buy Rating	Apr. 03	MT
Credit Suisse Downgrades Ascendis Pharma to Neutral From Outperform, Lowers Price Target to $82 From $130	Apr. 03	MT
Wedbush Raises Ascendis Pharma's Price Target to $195 From $164 After Model Adjustments, Keeps Outperform Rating	Mar. 06	MT
Oppenheimer Adjusts Ascendis Pharma's Price Target to $148 From $150, Maintains Outperform Rating	Feb. 17	MT
SVB Securities Adjusts Price Target on Ascendis Pharma to $163 From $148, Maintains Outperform Rating	Jan. 17	MT
Wells Fargo Boosts Price Target on Ascendis Pharma to $177 From $169, Keeps Overweight Rating	Jan. 03	MT
Morgan Stanley Adjusts Price Target on Ascendis Pharma to $148 From $146, Maintains Overweight Rating	Nov. 15	MT
Wedbush Raises Price Target on Ascendis Pharma to $164 From $151, Keeps Outperform Rating	Nov. 14	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features

Analyst Reco. Ascendis Pharma A/S

Equities

ASND

US04351P1012

Analyst Reco.

Filters